

# Johannes H Proost

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5820192/publications.pdf>

Version: 2024-02-01

54  
papers

1,481  
citations

361388

20  
h-index

315719

38  
g-index

57  
all docs

57  
docs citations

57  
times ranked

1506  
citing authors

#	ARTICLE	IF	CITATIONS
1	MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. <i>Computers in Biology and Medicine</i> , 1992, 22, 155-163.	7.0	308
2	A General Purpose Pharmacokinetic Model for Propofol. <i>Anesthesia and Analgesia</i> , 2014, 118, 1221-1237.	2.2	152
3	Optimal Sampling Strategy Development Methodology Using Maximum A Posteriori Bayesian Estimation. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 133-146.	2.0	71
4	Pharmacokinetics and pharmacodynamics of rocuronium at the vocal cords and the adductor pollicis in humans*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 185-191.	4.7	70
5	Evaluation of 5-Fluorouracil Pharmacokinetics in Cancer Patients with a C.1905+1G>A Mutation in DPYD by Means of a Bayesian Limited Sampling Strategy. <i>Clinical Pharmacokinetics</i> , 2012, 51, 163-174.	3.5	61
6	A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations. <i>Pharmaceutical Research</i> , 2017, 34, 333-351.	3.5	59
7	Performance of an Iterative Two-Stage Bayesian Technique for Population Pharmacokinetic Analysis of Rich Data Sets. <i>Pharmaceutical Research</i> , 2006, 23, 2748-2759.	3.5	52
8	Obesity and Allometric Scaling of Pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 2011, 50, 751-753.	3.5	43
9	Pharmacokinetics and Pharmacokinetic-Dynamic Relationship Between Rapacuronium (Org 9487) and Its 3-Desacetyl Metabolite (Org 9488). <i>Anesthesia and Analgesia</i> , 1999, 88, 640-647.	2.2	42
10	Renal function assessment in older adults. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, n/a-n/a.	2.4	39
11	Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4907-4913.	3.2	37
12	Structural Models Describing Placebo Treatment Effects in Schizophrenia and Other Neuropsychiatric Disorders. <i>Clinical Pharmacokinetics</i> , 2011, 50, 429-450.	3.5	34
13	Clinical Relevance of Pharmacological and Physiological Data in Intrathecal Baclofen Therapy. <i>Archives of Physical Medicine and Rehabilitation</i> , 2014, 95, 2199-2206.	0.9	34
14	Pharmacokinetic-Pharmacodynamic Modeling of the D2 and 5-HT2A Receptor Occupancy of Risperidone and Paliperidone in Rats. <i>Pharmaceutical Research</i> , 2012, 29, 1932-1948.	3.5	30
15	Pharmacokinetics and Pharmacokinetic-Dynamic Relationship Between Rapacuronium (Org 9487) and Its 3-Desacetyl Metabolite (Org 9488). <i>Anesthesia and Analgesia</i> , 1999, 88, 640-647.	2.2	29
16	An extended pharmacokinetic/pharmacodynamic model describing quantitatively the influence of plasma protein binding, tissue binding, and receptor binding on the potency and time course of action of drugs. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1996, 24, 45-77.	0.6	26
17	Modelling and Simulation of the Positive and Negative Syndrome Scale (PANSS) Time Course and Dropout Hazard in Placebo Arms of Schizophrenia Clinical Trials. <i>Clinical Pharmacokinetics</i> , 2012, 51, 261-275.	3.5	25
18	Wagner's Exact Loo&#x201c;Riegelman Equation: The Need for a Criterion to Choose Between the Linear and Logarithmic Trapezoidal Rule. <i>Journal of Pharmaceutical Sciences</i> , 1985, 74, 793-794.	3.3	24

#	ARTICLE	IF	CITATIONS
19	Population pharmacokinetics and pharmacodynamics in anesthesia, intensive care and pain medicine. <i>Current Opinion in Anaesthesiology</i> , 2010, 23, 479-484.	2.0	21
20	Pharmacokineticâ€“pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: The use of PANSS total score and clinical utility. <i>Schizophrenia Research</i> , 2013, 146, 144-152.	2.0	21
21	Mechanism-Based Pharmacokineticâ€“Pharmacodynamic Modeling of the Dopamine D2 Receptor Occupancy of Olanzapine in Rats. <i>Pharmaceutical Research</i> , 2011, 28, 2490-2504.	3.5	19
22	Pharmacokinetic/Pharmacodynamic Modeling of Rocuronium in Myasthenic Patients Is Improved by Taking into Account the Number of Unbound Acetylcholine Receptors. <i>Anesthesia and Analgesia</i> , 2002, 95, 588-596.	2.2	16
23	Prediction of the pharmacokinetics of succinylated human serum albumin in man from in vivo disposition data in animals and in vitro liver slice incubations. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 27, 123-132.	4.0	16
24	Population Pharmacokinetic-Pharmacodynamic Modeling of Haloperidol in Patients With Schizophrenia Using Positive and Negative Syndrome Rating Scale. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 731-739.	1.4	15
25	Pharmacokineticâ€“Pharmacodynamic Modeling of Rocuronium in Case of a Decreased Number of Acetylcholine Receptors. <i>Anesthesiology</i> , 2003, 98, 133-142.	2.5	14
26	Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy. <i>Pharmaceutical Research</i> , 2016, 33, 1003-1017.	3.5	14
27	Pharmacokinetics and whole body distribution of elastase derived angiotatin( $\kappa 1-3$ ) in rats. <i>International Journal of Cancer</i> , 2001, 91, 1-7.	5.1	13
28	Simultaneous versus sequential pharmacokineticâ€“pharmacodynamic population analysis using an Iterative Twoâ€“Stage Bayesian technique. <i>Biopharmaceutics and Drug Disposition</i> , 2007, 28, 455-473.	1.9	13
29	Combined proportional and additive residual error models in population pharmacokinetic modelling. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, S78-S82.	4.0	13
30	Pharmacokineticâ€“pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: Part II: The use of subscales of the PANSS score. <i>Schizophrenia Research</i> , 2013, 146, 153-161.	2.0	12
31	Development of a mechanistic biokinetic model for hepatic bile acid handling to predict possible cholestatic effects of drugs. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 115, 175-184.	4.0	12
32	Pharmacokinetics of Succinylated Serum Albumin in Wistar Rats and Cynomolgus Monkeys: Implications for Dosage Regimens in the Therapy of HIV Infection. <i>Drug Delivery</i> , 1996, 3, 165-171.	5.7	11
33	Dopamine D2 Receptor Occupancy as a Predictor of Catalepsy in Rats: A Pharmacokinetic-Pharmacodynamic Modeling Approach. <i>Pharmaceutical Research</i> , 2014, 31, 2605-2617.	3.5	11
34	Influence of Erroneous Patient Records on Population Pharmacokinetic Modeling and Individual Bayesian Estimation. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 526-534.	2.0	10
35	Limited-Sampling Strategies for Anidulafungin in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1177-1181.	3.2	10
36	Pharmacokinetics of a hepatic stellate cell-targeted doxorubicin construct in bile duct-ligated rats. <i>Biochemical Pharmacology</i> , 2007, 73, 1455-1462.	4.4	9

#	ARTICLE	IF	CITATIONS
37	Vancomycin pharmacokinetic model development in patients on intermittent online hemodiafiltration. PLoS ONE, 2019, 14, e0216801.	2.5	9
38	Modelling and simulation of placebo effect: application to drug development in schizophrenia. Journal of Pharmacokinetics and Pharmacodynamics, 2013, 40, 377-388.	1.8	8
39	Pharmacokinetics of Pancuronium in Patients Undergoing Coronary Artery Surgery With and Without Low Dose Dopamine. Clinical Pharmacokinetics, 1990, 19, 491-498.	3.5	6
40	Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia. Schizophrenia Research, 2013, 146, 53-58.	2.0	6
41	A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D <sub>2</sub> receptor antagonists in rats. European Journal of Pharmacology, 2016, 789, 202-214.	3.5	6
42	A Phase I/IIa Study with Succinylated Human Serum Albumin (Suc-HSA), a candidate HIV-1 Fusion Inhibitor. Antiviral Therapy, 2007, 12, 273-278.	1.0	6
43	Improving Pharmacokinetic-Pharmacodynamic Models of Muscle Relaxants Using Potentiation Modelling. Journal of Pharmacokinetics and Pharmacodynamics, 2005, 32, 143-154.	1.8	5
44	Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data. Therapeutic Drug Monitoring, 2019, 41, 59-65.	2.0	5
45	Disposition of glycosidase inhibitors in the isolated perfused rat liver: hepatobiliary and subcellular concentration gradients of 1-deoxymannojirimycin and N-methyl-1-deoxynojirimycin. Pharmaceutical Research, 1994, 11, 144-150.	3.5	4
46	Comment on: "Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients: Is Augmented Renal Clearance What We Really Want to Know? Some Suggested Management Approaches and Clinical Software Tools". Clinical Pharmacokinetics, 2017, 56, 311-312.	3.5	4
47	Pharmacokinetic modeling of gentamicin in treatment of infective endocarditis: Model development and validation of existing models. PLoS ONE, 2017, 12, e0177324.	2.5	4
48	Calculation of the Coefficient of Variation of Log-Normally Distributed Parameter Values. Clinical Pharmacokinetics, 2019, 58, 1101-1102.	3.5	4
49	Modeling of prolactin response following dopamine D <sub>2</sub> receptor antagonists in rats: can it be translated to clinical dosing?. Pharmacology Research and Perspectives, 2017, 5, e00364.	2.4	3
50	Clonidine as an Adjuvant to Prolong Local Analgesia in Conventional Scleral Buckle Surgery. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 777-782.	1.4	2
51	Population Pharmacodynamic Modeling Using the Sigmoid Emax Model: Influence of Inter-individual Variability on the Steepness of the Concentration-Effect Relationship. AAPS Journal, 2021, 23, 10.	4.4	2
52	Summary data of potency and parameter information from semi-mechanistic PKPD modeling of prolactin release following administration of the dopamine D <sub>2</sub> receptor antagonists risperidone, paliperidone and remoxipride in rats. Data in Brief, 2016, 8, 1433-1437.	1.0	1
53	Expert Discussion of the Role of Rate Constant Versus Clearance Approaches to Define Drug Pharmacokinetics: Theoretical and Clinical Considerations. AAPS Journal, 2020, 22, 25.	4.4	0
54	Association of long-term exposure to circulating platinum with adverse late effects in testicular cancer survivors.. Journal of Clinical Oncology, 2012, 30, 4528-4528.	1.6	0